CHINA SHINEWY P News

Express News | Shenwei Pharmaceutical: Revenue in the management accounts in the first quarter was 1,118 billion yuan without auditor review, a decrease of 6.1% over the previous year

BreakingsMay 6 12:12

CHINA SHINEWY P To Go Ex-Dividend On April 29th, 2024 With 1.17823 USD Dividend Per Share

April 3rd - $CHINA SHINEWY P(CSWYY.US)$ is trading ex-dividend on April 29th, 2024. Shareholders of record on April 30th, 2024 will receive 1.17823 USD dividend per share on June 3rd, 2024. The ex

Futu NewsApr 3 07:40

Express News | Shenwei Pharmaceutical announced annual results with profit attributable to shareholders of 970 million yuan, an increase of 34.14% over the previous year

BreakingsMar 28 12:22

Express News | Shenwei Pharmaceutical: Net profit attributable to company owners increased by about 30% to 36% year-on-year in 2023

BreakingsMar 7 16:52

CHINA SHINEWY P To Go Ex-Dividend On September 11th, 2023 With 0.30073 USD Dividend Per Share

August 31st - $CHINA SHINEWY P(CSWYY.US)$ is trading ex-dividend on September 11th, 2023. Shareholders of record on September 12th, 2023 will receive 0.30073 USD dividend per share on October 16th

Futu NewsAug 31, 2023 07:40

Pien Tsai's price increase boosts the industry! With favorable policies, may the traditional Chinese medicine sector welcome a new trend?

Price increases in Pien Tsai are expected to bring growth elasticity to pharmaceutical manufacturing revenue

Gelonghui FinanceMay 8, 2023 15:25

CHINA SHINEWY P To Go Ex-Dividend On April 28th, 2023 With 0.89937 USD Dividend Per Share

April 27th - $CHINA SHINEWY P(CSWYY.US)$ is trading ex-dividend on April 28th, 2023. Shareholders of record on May 1st, 2023 will receive 0.89937 USD dividend per share on June 1st, 2023. The ex-d

Futu NewsApr 27, 2023 09:09

Express News | Hong Kong stocks of traditional Chinese medicine continued to rise, Shenwei Pharmaceutical rose nearly 17%

BreakingsNov 14, 2022 14:04

Interim dividend 39 cents per share Shenwei Pharmaceutical's interim net profit increased by 21.6% to 308 million yuan compared with the same period last year.

Shenwei Pharmaceutical (02877) released its results for the six months ended June 30, 2021. The group made a profit of 1.554 billion yuan (the same unit below), an increase of 30.58% over the same period last year; a profit of 308 million yuan, an increase of 21.57% over the same period last year; and basic earnings per share of 41 points. The increase in net profit was lower than that of sales and the decline in net profit margin was mainly due to a total decrease of 42.2% in investment income and other income in the first half of this year compared with the same period last year. The operating profit before tax in the first six months of 2021, excluding investment income, other income, financial costs and taxes, was 2.98.

新浪港股Aug 31, 2021 12:31

Shenwei Pharmaceutical (02877.HK) held a board meeting on August 31st to approve the interim results.

Original title: Shenwei Pharmaceutical (02877.HK) held Board meeting on August 31 to approve interim results Source: Gelonghui August 19, Shenwei Pharmaceutical (02877.HK) announced that the board of directors will hold a board meeting on August 31, 2021 to, among other things, approve the release of the company's interim results for the six months ended June 30, 2021 and consider the declaration of an interim dividend.

金融界Aug 19, 2021 13:21

Morgan Stanley: maintain Shenwei Pharmaceutical (02877) "hold" rating target price increased by 13% to HK $7.80

Original title: big Motors: maintain Shenwei Pharmaceutical (02877) "hold" rating Target Price increased by 13% to HK $7.80 Source: Zhitong Financial APP has learned that JPMorgan has released a research report that the new dividend plan based on Shenwei Pharmaceutical (02877) actually guarantees 15% annual profit growth in the next few years, and raises its profit forecast for 2021-25 by 10% to 13%, which is expected to be mainly driven by an increase in sales. Forecast for an increase in the dividend payout ratio. Morgan Stanley updated its risk return to the company, raising its target price by 13% from HK $6.9 to HK $7.8, maintaining its "hold" rating.

金融界Jul 20, 2021 09:56

Changes in Hong Kong stocks | Shenwei Pharmaceutical (02877) soared by more than 7% in the afternoon and adopted the new dividend policy four times a year since 2022.

Original title: Hong Kong stocks change | Shenwei Pharmaceutical (02877) soared more than 7% in the afternoon to adopt a new dividend policy four times a year since calendar year 2022: Zitong Financial APP has learned that Shenwei Pharmaceutical (02877) announced that the company expects to declare and distribute a total dividend of 60 cents per share in calendar year 2021. In addition, the Board has approved and adopted a new dividend policy with effect from July 19, 2021. The stock surged more than 7 per cent in the afternoon and rose 6.75 per cent to HK $9.80 as of press time, with a turnover of HK $46.3467 million. Announcement show

金融界Jul 19, 2021 13:38

Shenwei Pharmaceutical (02877) adopts New dividend Policy

Shenwei Pharmaceutical (02877) announced that it expects to declare and distribute a total dividend of 60 cents per share in the calendar year 2021 (including the final dividend of 21 cents per share for the year ended 31 December 2021 paid on 17 June 2021). In addition, the Board has approved and adopted a new dividend policy with effect from July 19, 2021. As a result, the dividend policy stated in the company's 2020 report has been abolished.

智通財經網Jul 19, 2021 12:04

Shenwei Pharmaceutical (02877.HK) rose 10.22%.

Original title: [dynamic stock] Shenwei Pharmaceutical (02877.HK) rose 10.22% Source: Caihua net [Caihua Social News] Shenwei Pharmaceutical (02877.HK) rose 10.22% as of 14:24, and now reports HK $9.17, or HK $0.85. 4.8 million shares were traded, involving 41.9 million yuan. (source: FinetAI)

金融界Jul 15, 2021 14:24

Dahua Jixian: significantly increase the target price of Shenwei Pharmaceutical (02877.HK) to HK $11.80

Original title: Dahua Jixian: significantly raised the target price of Shenwei Pharmaceutical Company (02877.HK) to HK $11.8 Source: Caihua net [Caihua Social News] Dahuaxian released a report that substantially raised the target price of Shenwei Pharmaceutical Company (02877.HK) from the original HK $8.44 to HK $11.8, an increase of 39.8% or HK $6.52; the investment rating is "Buy". The report points out that Shenwei Pharmaceutical continues to recover from the novel coronavirus epidemic this year. As China opens up the traditional Chinese medicine formula granule industry to market competition, Shenwei is ready to expand the market. Shenwei Pharmaceutical Co., Ltd.

金融界Jun 1, 2021 13:45

神威药业(02877.HK)：中药配方颗粒快速增长，企业现金流充沛，维持"买入"评级，目标价8.67港元

原标题：神威药业(02877.HK)：中药配方颗粒快速增长，企业现金流充沛，维持"买入"评级，目标价8.67港元 来源：格隆汇 机构：国元证券 目标价：8.67港元 投资要点 中药注射液占比下降，口服产品贡献公司毛利达 72.3%： 公司口服类产品包括软胶囊、颗粒剂、中药配方颗粒及其他剂型，2019 年口服类产品持续发力实现 14.8 亿元营业收入，同比增速 20.8%，占总营收54.7%

金融界Dec 1, 2020 14:05

大摩：10月份销售数据表现强劲 上调神威药业(02877)目标价至6.7港元

原标题：大摩：10月份销售数据表现强劲 上调神威药业(02877)目标价至6.7港元 来源：智通财经网 智通财经APP获悉，大摩发布研究报告称，更新对神威药业(02877)的预测，公司10月份销售数据表现强劲，整体销售同比升29.4%，因此相应将盈利预测上调约4%，今年至2022年每股盈利预测升至0.61、0.69及0.74元人民币，预计公司明年注射剂销售将下跌8%，并预测软胶囊、颗粒剂及其

金融界Dec 1, 2020 10:59

大摩：升神威药业(02877)目标价至6.3元 评级“与大市同步”

原标题：大摩：升神威药业(02877)目标价至6.3元 评级“与大市同步” 来源：智通财经网 智通财经APP获悉，摩根士丹利发表报告，将神威药业(02877)目标价由5.9元升至6.3元，相当于预测明年市盈率9倍，维持“与大市同步”评级。 报告表示，基于神威药业今年第三季销售高于预期，尤其是注射剂及中药配方颗粒业务方面，故上调其2020至2022年度盈利预测6%至7%，分别至0.59、0.6

金融界Nov 5, 2020 12:11

神威药业(02877-HK)前九月营业额同比降8.3%至人民币18.80亿元

原标题：神威药业(02877-HK)前九月营业额同比降8.3%至人民币18.80亿元 来源：财华网 【财华社讯】神威药业(02877-HK)公布，截至2020年9月30日止九个月未经核数师审阅的管理账目內营业额为人民币18.80亿元(单位下同)，较2019年同期减少8.3%，分別是，注射液产品的营业额减少17.4%至7.87亿元；软胶囊产品的营业额增加0.5%至3.53亿元；颗粒剂产品的营业

金融界Nov 4, 2020 12:03

神威药业(02877-HK)半年少赚12%股息11分

原标题：神威药业(02877-HK)半年少赚12%股息11分 来源：财华网 【财华社讯】神威药业(02877-HK)公布，截至2020年6月30日止六个月营业额11.9亿元(人民币.下同)，按年下跌13.02%；溢利2.54亿元，按年下跌11.8%。每股盈利33分，派发中期息每股11分。 毛利率为73.6% ，而去年同期为71.3%；每股净资产7.1元(相等于7.8港元)；及每股净现金4.6

金融界Aug 28, 2020 13:07